J&J Announces Major Retirement, New Executive Appointments
On Jun 25, 2018
New Brunswick-based Johnson & Johnson announced that Sandra (Sandi) E. Peterson, group worldwide chairman for Johnson & Johnson, has announced her plans to retire from J&J effective October 1. The company also made new appointments to its executive committee.
During her career at Johnson & Johnson, Peterson exercised strong portfolio discipline in the businesses she has led, clarifying priority markets and segments, and shepherding numerous deals, acquisitions and divestitures. During her tenure, the Consumer business performance showed solid improvement, the U.S. OTC business was restored to growth, and the Vision Care business regained market leadership in contact lenses and has become a leader in eye health. In the past year, the Medical Device sector has made progress strengthening its foundation to improve performance and accelerate growth. Peterson has been instrumental in developing new partnerships in the areas of data science and technology for J&J.
“Sandi’s global mindset and passion for people have been hallmarks of her career, and influenced the work she’s done to better enable us to meet the needs of patients and consumers around the world,” said Alex Gorsky, chairman and chief executive officer of Johnson & Johnson. “She has been a dynamic business partner and inspirational leader, and I wish her all the best in this new chapter of her life.”
Peterson joined Johnson & Johnson in December of 2012. Prior to joining the company, she was chairman & chief executive officer of Bayer CropScience AG in Germany. She had previously served as CEO of Bayer Medical Care and president of Bayer HealthCare AG’s Diabetes Care Division. Earlier, Sandi held leadership roles at Medco Health Solutions (previously known as Merck-Medco), Nabisco, Whirlpool Corporation and McKinsey & Company.
J&J also announced new appointments to the company’s executive committee.
Joaquin Duato, executive vice president, worldwide chairman, Pharmaceuticals, and Dr. Paul Stoffels, executive vice president, chief scientific officer of Johnson & Johnson have been appointed to the position of vice chairman of the executive committee, effective July 2. Duato and Dr. Stoffels will continue to report to Alex Gorsky, chairman of the board and chief executive officer of Johnson & Johnson.
In his role as vice chairman of the executive committee, Duato will be responsible for the Pharmaceuticals and Consumer sectors, as well as Supply Chain, IT, Global Services, and the Health and Wellness businesses.
In his role as vice chairman of the executive committee, Dr. Stoffels will be responsible for Pharmaceutical Research & Development, Global Public Health, the Office of the Chief Medical Officer, External Innovation, Pharmaceuticals Business Development and Healthcare Technology.
Ashley McEvoy, company group chairman, Consumer Medical Devices, has been appointed executive vice president, worldwide chairman, Medical Devices, effective July 2. She will report to Gorsky and become a member of the executive committee.
Jennifer Taubert, company group chairman, The Americas, Pharmaceuticals, has been appointed executive vice president, worldwide chairman, Pharmaceuticals and named to the executive committee, effective July 2. She will report to Duato.
Kathy Wengel, worldwide vice president, Johnson & Johnson Supply Chain has been appointed executive vice president, chief global supply chain officer, and named to the executive committee, effective July 2. She will report to Duato.
Michael Sneed, worldwide vice president, global corporate affairs and chief communication officer, will become executive vice president, global corporate affairs and chief communication officer and a member of the executive committee, effective July 2. Sneed will also assume responsibility for the Global Design group. He will continue to report to Gorsky.